Semaglutide for the management of diabesity:The real-world experience  

作　　者：Mohammed Alkhalifah Hafsa Afsar Anindya Shams Dania Blaibel Vishnu Chandrabalan Joseph M Pappachan 

机构地区：[1]Department of Endocrinology and Metabolism,Lancashire Teaching Hospitals NHS Trust,Preston PR29HT,United Kingdom [2]Department of Family Medicine,King Faisal Specialist Hospital,Riyadh 11211,Saudi Arabia [3]Department of Data Science,Lancashire Teaching Hospitals NHS Trust,Preston PR29HT,United Kingdom [4]Faculty of Science,Manchester Metropolitan University,Manchester M156BH,United Kingdom [5]Faculty of Biology,Medicine&Health,The University of Manchester,Manchester M139PL,United Kingdom

出　　处：《World Journal of Methodology》2024年第3期68-77,共10页世界方法学杂志

摘　　要：BACKGROUND Diabesity(diabetes as a consequence of obesity)has emerged as a huge healthcare challenge across the globe due to the obesity pandemic.Judicious use of antidiabetic medications including semaglutide is important for optimal management of diabesity as proven by multiple randomized controlled trials.However,more real-world data is needed to further improve the clinical practice.AIM To study the real-world benefits and side effects of using semaglutide to manage patients with diabesity.METHODS We evaluated the efficacy and safety of semaglutide use in managing patients with diabesity in a large academic hospital in the United States.Several parameters were analyzed including demographic information,the data on improvement of glycated hemoglobin(HbA1c),body weight reduction and insulin dose adjustments at 6 and 12 months,as well as at the latest follow up period.The data was obtained from the electronic patient records between January 2019 to May 2023.RESULTS 106 patients(56 males)with type 2 diabetes mellitus(T2DM),mean age 60.8±11.2 years,mean durations of T2DM 12.4±7.2 years and mean semaglutide treatment for 2.6±1.1 years were included.Semaglutide treatment was associated with significant improvement in diabesity outcomes such as mean weight reductions from baseline 110.4±24.6 kg to 99.9±24.9 kg at 12 months and 96.8±22.9 kg at latest follow up and HbA1c improvement from baseline of 82±21 mmol/mol to 67±20 at 12 months and 71±23 mmol/mol at the latest follow up.An insulin dose reduction from mean baseline of 95±74 units to 76.5±56.2 units was also observed at the latest follow up.Side effects were mild and mainly gastrointestinal like bloating and nausea improving with prolonged use of semaglutide.CONCLUSION Semaglutide treatment is associated with significant improvement in diabesity outcomes such as reduction in body weight,HbA1c and insulin doses without major adverse effects.Reviews of largescale real-world data are expected to inform better clinical practice decision making to improve t

关 键 词：Type 2 diabetes mellitus DIABESITY Glucagon-like peptide 1 receptor agonists Semaglutide Insulin dose reduction Weight loss 

分 类 号：R587.1[医药卫生—内分泌]